Literature DB >> 33796516

Progressive Preretinal Fibrosis with Late, Ossifying, Proliferative Retinopathy following Treatment for Retinoblastoma.

Minh Nguyen1, Jessica Saunders2, M Cristina Pacheco2,3, Andrew W Stacey1,4.   

Abstract

We report a case of retinal atrophy and progressive preretinal fibrosis in an eye previously treated with intravenous and intra-arterial chemotherapy (IAC), which evolved immediately after treatment with intravitreal injection of melphalan. The atrophy and fibrosis progressed later to proliferative retinopathy with dystrophic ossification. The patient was originally diagnosed with bilateral retinoblastoma at 4 months of age and was treated with systemic chemotherapy followed by IAC. New vitreous seeds developed and required treatment with intravitreal chemotherapy. There was resolution of vitreous seeding after 2 doses of intravitreal melphalan, but clinically the eye developed new, widespread retinal atrophy and fibrosis within 1 month of the second injection. This was followed by phthisis and late proliferative retinopathy nearly 1 year later. Retinoblastoma specialists should be aware of this potential complication of combined chemotherapy treatments.
Copyright © 2020 by S. Karger AG, Basel.

Entities:  

Keywords:  Intravitreal melphalan; Preretinal fibrosis; Proliferative retinopathy; Retinoblastoma; Vitreous seeding

Year:  2020        PMID: 33796516      PMCID: PMC7989767          DOI: 10.1159/000509809

Source DB:  PubMed          Journal:  Ocul Oncol Pathol        ISSN: 2296-4657


  11 in total

1.  Clinicopathologic review of enucleated eyes after intra-arterial chemotherapy with melphalan for advanced retinoblastoma.

Authors:  Lejla Mutapcic Vajzovic; Timothy G Murray; Mohammed A Aziz-Sultan; Amy C Schefler; Cristina E Fernandes; Stacey C Quintero Wolfe; Ditte J Hess; Sander R Dubovy
Journal:  Arch Ophthalmol       Date:  2010-12

2.  Pathological findings in enucleated eyes after intravitreal melphalan injection.

Authors:  Fariba Ghassemi; Fahimeh Asadi Amoli
Journal:  Int Ophthalmol       Date:  2013-09-17       Impact factor: 2.031

3.  Profiling safety of intravitreal injections for retinoblastoma using an anti-reflux procedure and sterilisation of the needle track.

Authors:  Francis L Munier; Sameh Soliman; Alexandre P Moulin; Marie-Claire Gaillard; Aubin Balmer; Maja Beck-Popovic
Journal:  Br J Ophthalmol       Date:  2012-02-24       Impact factor: 4.638

4.  Acute Hemorrhagic Retinopathy following Intravitreal Melphalan Injection for Retinoblastoma: A Report of Two Cases and Technical Modifications to Enhance the Prevention of Retinal Toxicity.

Authors:  Hassan A Aziz; Jonathan W Kim; Francis L Munier; Jesse L Berry
Journal:  Ocul Oncol Pathol       Date:  2016-09-14

Review 5.  Retinoblastoma frontiers with intravenous, intra-arterial, periocular, and intravitreal chemotherapy.

Authors:  C L Shields; E M Fulco; J D Arias; C Alarcon; M Pellegrini; P Rishi; S Kaliki; C G Bianciotto; J A Shields
Journal:  Eye (Lond)       Date:  2012-09-21       Impact factor: 3.775

6.  Histopathologic findings in eyes with retinoblastoma treated only with chemoreduction.

Authors:  Hakan Demirci; Ralph C Eagle; Carol L Shields; Jerry A Shields
Journal:  Arch Ophthalmol       Date:  2003-08

7.  Intravitreal melphalan for refractory or recurrent vitreous seeding from retinoblastoma.

Authors:  Fariba Ghassemi; Carol L Shields
Journal:  Arch Ophthalmol       Date:  2012-10

8.  Clinicopathologic features of retinoblastoma after primary chemoreduction.

Authors:  N E Bechrakis; N Bornfeld; A Schueler; S E Coupland; G Henze; M H Foerster
Journal:  Arch Ophthalmol       Date:  1998-07

Review 9.  Ocular side effects following intravitreal injection therapy for retinoblastoma: a systematic review.

Authors:  Stephen J Smith; Brian D Smith; Brian G Mohney
Journal:  Br J Ophthalmol       Date:  2013-11-01       Impact factor: 4.638

10.  Atypical Retinal Pigment Epithelial Hyperplasia and Glial Proliferation Masquerading as Progressive Recurrent Retinoblastoma: A Case Report Review and Clinicopathologic Correlation.

Authors:  Emily Zolfaghari; Jonathan W Kim; Subramanian Krishnan; Patricia Chévez-Barrios; Jesse L Berry
Journal:  Ocul Oncol Pathol       Date:  2017-09-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.